세계의 골다공증 치료 시장 보고서(2025년)
Osteoporosis Treatment Global Market Report 2025
상품코드 : 1824430
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,469,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,350,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,232,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

골다공증 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연평균 복합 성장률(CAGR) 5.0%로 177억 3,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 좌식 생활 방식의 증가, 2차성 골다공증의 유병률의 상승, 가상 골절 클리닉, 골다공증의 유전자 치료, 남성의 뼈의 건강에 대한 주목 증가 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향은 생물 제제의 진보, 인공지능의 통합, 뼈 건강 기록의 블록 체인, 머신러닝의 통합 등을 포함합니다.

향후 5년간의 성장률 5.0%라고 하는 예측은 전회 예측으로부터 0.1%의 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 데노스맙 바이오시밀러(인도) 및 이중 에너지 X-선 흡수 측정 스캔 부품(벨기에)의 가격을 상승시켜 골다공증 진단 지연 및 내분비학적 검사 비용을 증가시켜 뼈의 건강 관리에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

골다공증의 유병률과 발병률의 상승은 향후 골다공증 치료 시장의 성장을 가속할 것으로 예측됩니다. 골다공증은 뼈의 강도와 조성에 변화가 생기거나 골량과 미네랄 밀도가 저하됨으로써 발생하는 뼈의 질병입니다. 대부분의 골다공증 치료제는 뼈의 열화를 지연시킴으로써 효과를 발휘하지만, 에스트로겐과 같은 호르몬 기반 치료는 특히 폐경 직후 시작시 골밀도를 유지하는 데 도움이 됩니다. 예를 들어, 2022년 5월 미국 바이오의약품 기업인 암젠은 골다공증과 연관된 골절의 연간 건수가 68% 증가하고 2040년에는 320만 건에 이를 것으로 예측했습니다. 게다가 2022년 4월, 국립의학 도서관은 영국에서는 연간 약 54만 9000건의 취약성 골절이 새롭게 기록되어 그 3분의 1이 남성에게 발생하고 있다고 보고했습니다. 노화로 인해 이 수치는 2030년까지 19.6% 증가할 것으로 예측됩니다. 그 결과, 골다공증의 유병률과 발생률 증가가 골다공증 치료 시장의 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Osteoporosis treatment encompasses medical interventions designed to manage and improve the condition of osteoporosis. This bone disease occurs when there is a decline in bone mass and mineral density, or when the composition and strength of bones change. The primary goals of osteoporosis treatment are to stop bone deterioration, reduce the risk of fractures, and enhance overall bone health.

Key pharmaceuticals involved in osteoporosis treatment include bisphosphonates, calcitonin, hormone therapy, selective estrogen receptor modulators (SERMs), parathyroid hormone-related protein (PTHrP) analog, and rank ligand (RANKL) inhibitor. Bisphosphonates, recognized for their efficacy in relieving bone discomfort associated with certain cancers and hypercalcemia, are pivotal in preventing osteoporotic fractures. These medications can be administered orally, through injections, and other modalities, with distribution channels spanning hospitals, retail pharmacies, stores, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The osteoporosis treatment research report is one of a series of new reports from The Business Research Company that provides osteoporosis treatment market statistics, including the osteoporosis treatment industry's global market size, regional shares, competitors with osteoporosis treatment market share, detailed osteoporosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis treatment industry. This osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteoporosis treatment market size has grown steadily in recent years. It will grow from $13.96 billion in 2024 to $14.57 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to aging population demographics, hormone replacement therapies, calcium and vitamin d supplementation, increased diagnostic tools, integration of digital health solutions.

The osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $17.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to rise in sedentary lifestyles, rising prevalence of secondary osteoporosis, virtual bone fracture clinics, gene therapy for osteoporosis, increased focus on men's bone health. Major trends in the forecast period include advancements in biologics, integration of artificial intelligence, blockchain in bone health records, integration of machine learning.

The forecast of 5.0% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder bone health management by inflating prices of denosumab biosimilars (India) and Dual-energy X-ray absorptiometry scan components (Belgium), resulting in delayed osteoporosis diagnoses and higher endocrinology testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence and incidence of osteoporosis are anticipated to drive the growth of the osteoporosis treatment market in the future. Osteoporosis is a bone disease that occurs when there are changes in bone strength and composition, or when there is a decline in bone mass and mineral density. Most osteoporosis medications work by slowing the deterioration of bones, while hormone-based treatments, such as estrogen, can help maintain bone density, particularly when started shortly after menopause. For example, in May 2022, Amgen, a US-based biopharmaceutical company, projected that the annual number of osteoporosis-related fractures could rise by 68%, reaching 3.2 million by 2040. Additionally, in April 2022, the National Library of Medicine reported that approximately 549,000 new fragility fractures are recorded annually in the UK, with one-third of these cases occurring in men. Due to the aging population, this figure is expected to increase by 19.6% by 2030. Consequently, the growing prevalence and incidence of osteoporosis are fueling the expansion of the osteoporosis treatment market.

The growth of the osteoporosis treatment market is fueled by the escalating healthcare expenditures. Healthcare expenditures encompass the total spending on healthcare services and products within a specific timeframe. Osteoporosis treatment contributes significantly to the rising healthcare costs, covering expenses for diagnostic tests, medications, rehabilitation services, and potential surgeries. In November 2022, the CIHI projected a 0.8% increase in total health spending in Canada, from $328 billion in 2021 to $331 billion in 2022, underscoring the market's expansion facilitated by the surge in healthcare expenditures.

Major companies in the osteoporosis treatment market are concentrating on the development of advanced injectable therapies to maintain their competitive edge. Injectable osteoporosis treatments are administered through injections to help prevent bone loss and lower fracture risk in individuals with osteoporosis. These treatments provide a direct approach to improving bone density and enhancing skeletal health. For example, in November 2023, Apotex Corp., a Canada-based pharmaceutical company, introduced Teriparatide Injection. This pre-filled pen is designed for single-patient use in the treatment of osteoporosis, featuring a concentration of 250 mcg/mL and offering 28 daily doses of 20 mcg each per pen. This product aims to improve access to affordable treatment for approximately 10 million Americans affected by osteoporosis. Its development highlights Apotex's commitment to producing complex generic medications, ensuring that patients have access to high-quality treatment.

Leading companies in the osteoporosis treatment market are strategically focusing on the development of derivative capsules, particularly those containing vitamin D3, to attain a competitive advantage. In December 2022, Chugai Pharmaceutical Co., Ltd., based in Tokyo, collaborated with Towa Pharmaceutical, a Japan-based counterpart, to launch 'Edirol Tablets 0.5 µg/0.75 µg.' These capsules, featuring an active vitamin D3 derivative, are tailored for the treatment of osteoporosis. Specifically designed to enhance bone and calcium metabolism, Edirol Tablets aim to reduce vertebral fractures and increase bone mineral density, exemplifying the companies' commitment to cutting-edge solutions.

In May 2023, Abiogen Pharma, an Italy-based specialist in osteoarticular and bone metabolism diseases, acquired a 97.09% stake in EffRx Pharmaceuticals. This strategic acquisition, conducted for an undisclosed amount, serves to strengthen Abiogen Pharma's global presence and underscores its dedication to bone health and rare diseases. EffRx Pharmaceuticals, headquartered in Switzerland, possesses a portfolio that includes products for the treatment of postmenopausal osteoporosis, aligning with Abiogen Pharma's broader objectives in the field.

Major companies operating in the osteoporosis treatment market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck and Co Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline Pharmaceutical Ltd., Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Corporation, AstraZeneca Plc., Viatris Inc., Teva Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Ltd, Dr. Reddy's Laboratories, Gedeon Richter Plc., Celltrion Inc., Luye Pharma Group, Ligand Pharmaceuticals Incorporated, Radius Health Inc., Haoma Medica Ltd., EffRx Pharmaceuticals SA

North America was the largest region in the osteoporosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis treatment market consists of revenues earned by entities by providing osteoporosis services such as physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoporosis treatment market also includes sales of alendronate, risedronate, Ibandronate, and zoledronic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for osteoporosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The osteoporosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

4) By Selective Estrogen Receptor Modulators (SERMs); Raloxifene; Bazedoxifene

Table of Contents

1. Executive Summary

2. Osteoporosis Treatment Market Characteristics

3. Osteoporosis Treatment Market Trends And Strategies

4. Osteoporosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Osteoporosis Treatment Growth Analysis And Strategic Analysis Framework

6. Osteoporosis Treatment Market Segmentation

7. Osteoporosis Treatment Market Regional And Country Analysis

8. Asia-Pacific Osteoporosis Treatment Market

9. China Osteoporosis Treatment Market

10. India Osteoporosis Treatment Market

11. Japan Osteoporosis Treatment Market

12. Australia Osteoporosis Treatment Market

13. Indonesia Osteoporosis Treatment Market

14. South Korea Osteoporosis Treatment Market

15. Western Europe Osteoporosis Treatment Market

16. UK Osteoporosis Treatment Market

17. Germany Osteoporosis Treatment Market

18. France Osteoporosis Treatment Market

19. Italy Osteoporosis Treatment Market

20. Spain Osteoporosis Treatment Market

21. Eastern Europe Osteoporosis Treatment Market

22. Russia Osteoporosis Treatment Market

23. North America Osteoporosis Treatment Market

24. USA Osteoporosis Treatment Market

25. Canada Osteoporosis Treatment Market

26. South America Osteoporosis Treatment Market

27. Brazil Osteoporosis Treatment Market

28. Middle East Osteoporosis Treatment Market

29. Africa Osteoporosis Treatment Market

30. Osteoporosis Treatment Market Competitive Landscape And Company Profiles

31. Osteoporosis Treatment Market Other Major And Innovative Companies

32. Global Osteoporosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteoporosis Treatment Market

34. Recent Developments In The Osteoporosis Treatment Market

35. Osteoporosis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기